A Phase 1, Randomized, Open-label, Parallel-group Study Comparing Pharmacokinetic Properties Of Garadacimab Administered By Subcutaneous Pre-filled Syringe Assembled To Autoinjector/Pre-filled Pen Versus Pre-filled Syringe Assembled To Needle Safety Device In Healthy Adults - 05/02/24
Doi : 10.1016/j.jaci.2023.11.046
Fiona Glassman, PhD 1, John-Philip Lawo, PhD 2, Alex Bica, MD 2, Anthony Roberts, PhD 3, David Kormann, PhD 1, Soeren Miethke, PhD 4, Iwona Dziadowiec, PhD 4, Stephen Caltabiano, PhD 1, Iris Jacobs, MD 1, Thomas Puchalski, PhD 1
1 CSL Behring, King of Prussia, PA, USA
2 CSL Behring Innovation GmbH, Marburg, Germany
3 CSL Innovation Pty Ltd., Parkville, Victoria, Australia
4 CSL Behring AG, Bern, Switzerland
020
El texto completo de este artículo está disponible en PDF.Esquema
© 2023
Vol 153 - N° 2S
P. AB7 - février 2024 Regresar al número
Artículo precedente
- Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
- David Rosmarin, Andreas Wollenberg, Mark Boguniewicz, Carolyn Jack, Sebastien Barbarot, Vivian Shi, Marjolein de Bruin-Weller, Louise DeLuca-Carter, Evangeline Pierce, Chaoran Hu, Chunyuan Liu, Heidi Crane, Laia Bardolet, Martin Steinhoff
- Demographics and Baseline Characteristics of Children With Atopic Dermatitis Enrolled in a Randomized Phase 3 Study (TRuE-AD3)
- Dareen Siri, Lara Wine Lee, Linda Stein Gold, April Armstrong, Kanwaljit Brar, Kristen Holland, Julie Shepard, Alim Devani, Daniel Sturm, Brett Angel, Qian Li, Lawrence Eichenfield
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?